Detalhe da pesquisa
1.
Rituximab versus obinutuzumab-based first-line chemoimmunotherapy for follicular lymphoma-a real-world multicenter retrospective cohort study.
Ann Hematol
; 102(8): 2127-2136, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37335322